Moreover, in recent years, DDR components have become accepted as attractive therapeutic targets for cancer therapy, with numerous small molecule inhibitors targeting DNA repair enzymes now being explored clinically and with inhibitors of the DNA-repair enzyme PARP being approved for treating various tumor types (Piliè et al. 2019). This evidence concerns the gene PARP1 and neoplasm.